Pfizer's Strategic Plan
PFIZER INC.
Pfizer Strategic Plan
Date Submitted: May 25, 2005 Pfizer's Strategic Plan: Overview
Executive Summary
Pfizer is a New York City based major drug producer, ranking first in pharmaceutical sales in the U.S., with 2005 revenues of 56.7 billion. With almost 60 billion in Revenue, Pfizer remains the industry's behemoth, overseeing the most ambitious research agenda for any company in the world. Pfizer's is spending on R&D supports 12,000 scientists. Pfizer's research increased 3 percent in 2004, to 7.7 billion, after a 2003 increase of 44 percent that is attributable to the acquisition of Pharmacia. At the end of 2004, Pfizer had 225 projects in 18 therapeutic areas under active development. Pfizer is studying 145 new molecular entities and 80 extensions of existing drugs. An additional 400 compounds are in discovery phase of testing. In 2004, 43 discovery projects advanced into preclinical testing; 23 projects moved from preclinical research into human trials. Pfizer has eight subsidiaries, divisions and affiliates, and has over 120,000 employees worldwide (Pfizer, 2005). There are four main divisions at Pfizer, consisting of Healthcare, Consumer Care, Food Science, and Animal Health. Pfizer manufactures its products in 150 countries. Pfizer has sales offices in every state, and has Corporate Research Center in Groton, CT, Corporate Headquarters in New York, NY and International Headquarters in Nagoya, Japan and Sandwich, England. The executive members of Pfizer coupled with the reviews from Wall Street and the 50 percent cut in company stock in 2001 has forced Pfizer to demand more accountability from all of it's 115,000 employees world wide. Pfizer realizes that their operating expenses, their size, and their attention to detail has suffered due primarily to their size. Pfizer has also accepted that by the year 2010 (Pfizer, 2005). Politicians and Economist believe that Pfizer has to trim some of the fat from the hostile takeover of Warner
Pfizer Strategic Plan
Date Submitted: May 25, 2005 Pfizer's Strategic Plan: Overview
Executive Summary
Pfizer is a New York City based major drug producer, ranking first in pharmaceutical sales in the U.S., with 2005 revenues of 56.7 billion. With almost 60 billion in Revenue, Pfizer remains the industry's behemoth, overseeing the most ambitious research agenda for any company in the world. Pfizer's is spending on R&D supports 12,000 scientists. Pfizer's research increased 3 percent in 2004, to 7.7 billion, after a 2003 increase of 44 percent that is attributable to the acquisition of Pharmacia. At the end of 2004, Pfizer had 225 projects in 18 therapeutic areas under active development. Pfizer is studying 145 new molecular entities and 80 extensions of existing drugs. An additional 400 compounds are in discovery phase of testing. In 2004, 43 discovery projects advanced into preclinical testing; 23 projects moved from preclinical research into human trials. Pfizer has eight subsidiaries, divisions and affiliates, and has over 120,000 employees worldwide (Pfizer, 2005). There are four main divisions at Pfizer, consisting of Healthcare, Consumer Care, Food Science, and Animal Health. Pfizer manufactures its products in 150 countries. Pfizer has sales offices in every state, and has Corporate Research Center in Groton, CT, Corporate Headquarters in New York, NY and International Headquarters in Nagoya, Japan and Sandwich, England. The executive members of Pfizer coupled with the reviews from Wall Street and the 50 percent cut in company stock in 2001 has forced Pfizer to demand more accountability from all of it's 115,000 employees world wide. Pfizer realizes that their operating expenses, their size, and their attention to detail has suffered due primarily to their size. Pfizer has also accepted that by the year 2010 (Pfizer, 2005). Politicians and Economist believe that Pfizer has to trim some of the fat from the hostile takeover of Warner